Skip to Content

Publications.

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

Multiple Sclerosis Journal-ETC Matthijs Versteegh 8/8/23 Multiple Sclerosis Journal-ETC Matthijs Versteegh 8/8/23

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

Read More

Huygens & Versteegh B.V.
Chamber of commerce: 85221155
Contact